Paper · 28298040
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A and 9 others. J Neurosurg, 2018. Cited by 69 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Papers, record 28298040. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28298040
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| Glioma | Major topic |
| Isocitrate Dehydrogenase | Major topic |
| Magnetic Resonance Spectroscopy | Major topic |
| Mutation | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| DNA Mutational Analysis | |
| Female | |
| Glutarates | |
| Humans | |
| Image-Guided Biopsy | |
| Immunohistochemistry | |
| Magnetic Resonance Imaging | |
| Male | |
| Middle Aged | |
| Polymerase Chain Reaction | |
| Prognosis | |
| Sensitivity and Specificity | |
| Young Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA154843 | NCI NIH HHS | United States | R01CA154843 | PubMed |
Source NIH RePORTER
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,344,220 | Treatment of Isocitrate Dehydrogenase-Mutant Gliomas. | Adv Oncol | 2025 | https://conductscience.org/library/papers/42344220 | PubMed |
| 41,995,710 | Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41995710 | PubMed |
| 41,698,848 | Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives. | Neuro Oncol | 2026 | https://conductscience.org/library/papers/41698848 | PubMed |
| 40,248,613 | Diagnostic and theranostic opportunities in Neuro-oncology. | Adv Oncol | 2024 | https://conductscience.org/library/papers/40248613 | PubMed |
| 39,796,751 | Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39796751 | PubMed |
| 39,596,840 | IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications. | Biology (Basel) | 2024 | https://conductscience.org/library/papers/39596840 | PubMed |
| 39,556,508 | Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas. | Ann Clin Transl Neurol | 2025 | https://conductscience.org/library/papers/39556508 | PubMed |
| 39,382,639 | Advanced imaging techniques and non-invasive biomarkers in pediatric brain tumors: state of the art. | Neuroradiology | 2024 | https://conductscience.org/library/papers/39382639 | PubMed |
| 38,997,123 | Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH-Mutant Glioma. | AJNR Am J Neuroradiol | 2025 | https://conductscience.org/library/papers/38997123 | PubMed |
| 38,802,883 | 7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading. | Cancer Imaging | 2024 | https://conductscience.org/library/papers/38802883 | PubMed |
1 to 10 of 51
See all 51 cited byGenes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IDH1 | 3,417 | PubTator's text mining | https://conductscience.org/library/genes/3417 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28298040
GET https://conductscience.org/api/papers/v1/28298040/cited_by?page=2